Trend of A-share and Hong Kong stock innovative drug sector this week
In the fourth week of March 2022, a total of 28 stocks in the innovative drug sector in mainland and Hong Kong rose and 24 stocks fell. Among them, the top three gainers were zaiding pharmaceutical-sb (+ 29.29%), Chuangsheng group-B (+ 17.89%) and Deqi pharmaceutical-b (+ 13.27%). The decline was – 64.5% for Sumitomo (- U-21%), and – 64.5% for Sumitomo (- b). This week, the A-share innovative drug sector fell 2.66%, underperforming the CSI 300 index by 2.14pp, and biomedicine rose 0.11%. Over the past six months, A-share innovative drugs have fallen by 15.02%, underperforming the CSI 300 index by 14.18pp, and biomedicine has fallen by 19.99%. This week, the innovative drug sector of Hong Kong stocks rose 4.86%, outperforming the Hang Seng Index by 0.04pp, and Hang Seng healthcare rose 2.21%. Over the past six months, innovative drugs in Hong Kong stocks have fallen by 15.83%, underperforming the Hang Seng Index by 13.06pp, and Hang Seng health care has fallen by 31.82%.
Progress of key innovative drugs in China
In March, a total of 10 new drugs were approved for marketing in China. This week, four drugs were approved for listing in China, and three innovative drugs were approved for new indications. The new drug approved for marketing is: bougatinib of Takeda pharmaceutical for the treatment of ALK positive advanced non-small cell lung cancer. Fluglizumab of Fuhong Hanlin is used to treat adult patients with advanced solid tumors with unresectable or metastatic microsatellite instability high (MSI-H). Abbvie’s upatinib is used to treat adult patients with moderate to severe active rheumatoid arthritis with poor response or intolerance to one or more TNF inhibitors. Zerun bio’s recombinant human papillomavirus bivalent (type 16 / 18) vaccine (yeast) is used to prevent diseases caused by high-risk HPV16 / 18, such as cervical cancer. The newly approved indications are: Haisco Pharmaceutical Group Co.Ltd(002653) of cyclophenol injection is approved for sedation and anesthesia, induction and maintenance of general anesthesia in non endotracheal intubation surgery / operation. Novartis’s darafinil mesylate and trimetinib have been approved for the combined treatment of patients with brafv600 mutation positive advanced non-small cell lung cancer.
Progress of overseas key innovative drugs
In March, 10 new drugs were approved by FDA. Four new drugs were approved this week. In March, no new drugs were approved in Europe. In March, three new drugs were approved for marketing in Japan. No new drugs have been approved this week.
This week’s small topic – research and development progress of DPP-4 target
There are 95 DPP-4 inhibitors under development in the world, including 26 approved for listing, 1 applied for listing, 13 in phase III, 1 in phase II / III, 13 in phase II, 1 in phase I / II and 18 in phase I. There are 23 under research in China, including 1 application for listing ( Jiangsu Hengrui Medicine Co.Ltd(600276) ), 5 phase III clinical, 1 phase II clinical and 8 phase I clinical.
Progress of global key innovative drug transactions this week
This week, there were 8 key transactions in the world, and there were 3 key transactions with disclosed amount, involving companies including Bavarian Nordic and yourui medicine, volastra therapeutics and Bristol Myers Squibb, halozyme therapeutics and Chugai pharmaceutical.
Risk warning: drug price reduction risk; Risk that the implementation progress of medical reform policy is lower than expected; Risk of R & D failure.
